Objectives: A high-dose 12 mg/kg/day (6 mg/kg twice daily) voriconazole regimen was recommended by the CDC to treat patients injected with contaminated methylprednisolone acetate that caused a multi-state fungal outbreak in 2012-13. Therapeutic drug monitoring results of this unique regimen are unknown, as is the most appropriate dosing weight for obese patients. We evaluated voriconazole trough measurements for this dosing scheme, as well as the use of adjusted body weight dosing for obese patients. Results: Of 138 patients, the first steady-state voriconazole troughs were supratherapeutic (.5 mg/L) in 65 (47%) patients, therapeutic (2-5 mg/L) in 57 (41%) patients and subtherapeutic (,2 mg/L) in 16 (12%) patients. Twenty-three patients had pre-steady-state dose decreases due to supratherapeutic levels, with subsequent first steady-state troughs in the therapeutic (n " 17) and subtherapeutic (n " 6) categories. Voriconazole doses .11 and .8 mg/kg/day produced mainly first steady-state supratherapeutic troughs in 44 obese and 94 nonobese patients, respectively. An initial 12 mg/kg/day was progressively lowered to a median maintenance dose of 8.5 mg/kg/day in the obese and 8.6 mg/kg/day in the non-obese.
Introduction
In October 2012 the CDC announced a multi-state outbreak of fungal infections in patients who had received contaminated methylprednisolone acetate injections supplied by a single compounding pharmacy in Massachusetts, USA. [1] [2] [3] Of the 751 cases, 195 patients with meningitis, spinal/paraspinal and peripheral joint infections associated with these injections were cared for at St Joseph Mercy Hospital (SJMH) in Ann Arbor, Michigan, USA. The predominant fungus implicated in this unprecedented event was Exserohilum rostratum, a brown-black mould that had rarely been described to cause human disease. 4 With a paucity of human data to refer to, the CDC recommended treatment with voriconazole monotherapy, plus the option to add liposomal amphotericin B in severe disease, based primarily on small case series and expert opinion. [5] [6] [7] [8] For patients with suspected CNS involvement, in order to achieve adequate CNS penetration the CDC suggested initiating therapy with highdose voriconazole at 12 mg/kg/day (as 6 mg/kg twice daily). This dosing suggestion was greater than the manufacturer's suggested regimen for invasive fungal infections of two 6 mg/kg loading doses followed by 8 mg/kg/day (as 4 mg/kg twice daily). 9 For dosing of voriconazole in obese patients the CDC recommended discussion with an infectious diseases physician. 5 Therapeutic drug monitoring (TDM) was also suggested, aiming for a trough level of 2-5 mg/L, with the level to be drawn on day 5 of therapy. Previous voriconazole TDM studies that recommended a similar therapeutic range reported initial maintenance doses no higher than 8 mg/kg/day. [10] [11] [12] [13] We report TDM results for high-dose voriconazole therapy and describe the results of using an adjusted body weight dosing strategy for obese patients.
Methods

Patients and setting
This was a retrospective study performed at SJMH, a 537 bed, nonuniversity-affiliated, community-teaching hospital. Antifungal therapy for all patients was managed by both Infectious Diseases and Pharmacy staff.
Ethics
The study was approved by the Institutional Review Board, and a waiver of informed consent was granted.
Study design and definitions
Patients started on high-dose 12 mg/kg/day voriconazole for a CNS (meningitis, stroke or arachnoiditis) and/or spinal/paraspinal infection (epidural or paraspinal abscess/phlegmon, discitis/osteomyelitis or sacroiliac infection) were included. Patients were excluded if initiation of therapy occurred at another institution. Non-obese patients were defined as having a BMI ,35 kg/m 2 , while obese patients were categorized as having a BMI 35 kg/m 2 (CDC class 2 and 3 obesity definitions). 14 Doses were calculated via total body weight in non-obese patients, and obese patients were dosed using an adjusted body weight. The equation used to calculate adjusted body weight was [(total body weight -ideal body weight) % 0.4] ! ideal body weight. Doses were rounded to the nearest 50 mg for both intravenous and oral formulations of voriconazole.
To better define a steady-state trough level of voriconazole, we used the following specific criteria in our study: drawn after at least nine doses of an every 12 h schedule of the same mg/kg/day regimen, within 3 h of the next dose, and with no missed doses in the three scheduled doses prior to the trough. A therapeutic trough level of voriconazole was 2-5 mg/L as defined by the CDC. 5 We considered a patient to have arrived at their voriconazole maintenance dose when they were continued on the same mg/kg/day regimen that produced three consecutive trough levels, each at least 5 days apart, in the 2-5 mg/L range.
Dosing outcomes of interest were: the percentage of first steadystate voriconazole trough levels that were supratherapeutic, therapeutic and subtherapeutic; the number of patients who had levels drawn and dose decreases before steady-state and subsequent troughs; the median voriconazole dose associated with the first steady-state trough and the first steady-state therapeutic trough; and the median voriconazole maintenance dose. These outcomes were analysed separately in two groups: obese and non-obese. We also report the median number of days from voriconazole initiation to the first steady-state and therapeutic troughs. Patient serum samples were analysed by Mayo Medical Laboratories using LC-MS/MS and results usually returned 2-4 days after draw time.
Statistical analysis
All analyses were done using SPSS version 22.0. Patient demographic and clinical data were summarized using means, medians or percentages, as appropriate. An independent sample t-test was used for continuous variables and a v 2 test was used for nominal data, with P , 0.05 deemed statistically significant.
Results
Of 195 patients treated at SJMH for fungal infections associated with contaminated methylprednisolone, 140 received the highdose 12 mg/kg/day voriconazole regimen. There were 46 (33%) patients in the obese subset, and their total body weight and BMI were significantly greater than the 94 non-obese patients (P , 0.001) ( Table 1 ). Two of the obese patients were excluded only from the first steady-state trough/dose portion, as total body weight was used for their initial dosing ( Figure 1 ). Of the remaining 138 patients, the first steady-state voriconazole troughs were supratherapeutic (levels .5 mg/L) in 65 (47%), therapeutic (2-5 mg/L) in 57 (41%), and subtherapeutic (trough ,2 mg/L) in 16 (12%). Forty-five (32%) patients had levels drawn and doses High-dose voriconazole monitoring and adjusted weight dosing JAC decreased before reaching steady-state. Of these 45 patients, 36 (7 obese, 29 non-obese) had an elevated pre-steady-state voriconazole level, and the subsequent reduction(s) in voriconazole dose resulted in most patients dropping out of the supratherapeutic range. The remaining nine patients had pre-steady-state levels in the therapeutic range, and their doses were decreased due to adverse effects of voriconazole (hallucinations, photopsia and transaminitis).
In the obese cohort, utilization of the adjusted body weight dosing strategy for voriconazole resulted in a higher percentage of therapeutic first steady-state troughs when compared with the non-obese group (50% versus 37%) ( Table 1) . The proportion of patients with supratherapeutic troughs was slightly lower in the obese group compared with the non-obese group, and there were fewer subtherapeutic trough levels in the obese population (5% versus 15%) ( Table 1) .
For the obese group, the median voriconazole dose at the time (median day 8) of the first steady-state trough was nearly identical to the recommended 12 mg/kg/day, at 11.8 mg/kg/day. In the non-obese cohort, the median dose at the first steady-state trough (median day 10) was lower, at 10.3 mg/kg/day (Table 2 ). In the obese group, dosage ranges of 7-8 and 9-11 mg/kg/day produced mainly therapeutic first steady-state troughs, whereas 12 mg/kg/day resulted in a high proportion (60%) of supratherapeutic levels (Figure 2 ). In the non-obese group, a 7-8 mg/kg/day dosage range resulted in levels predominantly in the therapeutic range, whereas doses of 9 mg/kg/day or higher led to predominantly supratherapeutic troughs (Figure 3 ). There were 6 patients in the obese group and 8 patients in the nonobese group whose dose at the first steady-state trough was .12 mg/kg/day, with 12 of these the result of dose rounding to the nearest 50 mg. The two exceptions were one patient from each weight category who was receiving a dose .12 mg/kg/day in response to a subtherapeutic pre-steady-state level. The time to the first steady-state therapeutic trough was a median of 23 days in both the obese (range 4-46 days) and non-obese groups (range 4-144 days).
In total, 102 patients, comprising 32/46 (70%) obese and 70/94 (74%) non-obese patients, achieved a stable voriconazole maintenance dose ( Table 2 ). The median maintenance dose for each group was nearly identical, but approximately one-third lower than the recommended initial 12 mg/kg/day dosing regimen (Table 2) . Conversely, a maintenance dose of voriconazole .12 mg/kg/day was required to sustain therapeutic levels in five (four non-obese, one obese) patients. The maintenance dose range in these patients was 13.5-14.8 mg/kg/day, and included one patient who required three-times daily dosing of voriconazole.
Discussion
In this study, we found that 65 of 138 (47%) patients who received high-dose 12 mg/kg/day voriconazole had supratherapeutic voriconazole trough levels. However, the proportion of patients who had supratherapeutic troughs would most likely have been higher had 23 (5 obese, 18 non-obese) patients who had a Did not receive 12 mg/kg/day voriconazole regimen (n " 48), therapy initiated outside institution (n " 7).
b Excluded from first steady-state trough due to initial dosing based on total body weight rather than adjusted body weight.
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pre-steady-state supratherapeutic levels not had their doses decreased before the steady-state measurements were taken. If all of these patients were added to the supratherapeutic group, the percentage of supratherapeutic first steady-state troughs would increase to 88 (64%) from 65 (47%). Particularly in the early phase of the outbreak, clinicians recommended pre-steady-state levels be drawn on day 3, due to the unknown pharmacokinetics of the high-dose voriconazole regimens. In the first 4 weeks of our study period, half of the total first steady-state cohort (n " 69) were initiated on voriconazole and 25 (36%) of those had presteady-state dose decreases in response to elevated pre-steadystate levels. This compares to just 11 (16%) of the remaining 69 patients experiencing pre-steady-state decreases over the subsequent 27 weeks of therapy initiation, with less aggressive monitoring being employed as providers became more comfortable and experienced with managing voriconazole therapy. Based on previous studies, it was not unexpected that most patients' first steady-state trough was supratherapeutic on the 12 mg/kg/day voriconazole regimen. 10, 12 A study of 201 patients by Dolton et al. 10 recommended a 2-5 mg/L therapeutic range of voriconazole, identical to the CDC's 5 recommendation in the multistate fungal outbreak, to ensure efficacy and minimize toxicity. The median maintenance voriconazole dose was 6.1 mg/kg/day (range 2.4-17.4 mg/kg/day) in their study, essentially half of the starting dose in our cohort. 10 In an earlier study, by Pascual et al.,
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a voriconazole trough range of 1-5.5 mg/L was identified to improve efficacy and safety. The median dose in patients achieving voriconazole levels .1 mg/L was 8 mg/kg/day in their investigation. 12 Both of these studies utilized total body weight for dosing of voriconazole in all patients, regardless of body habitus. In our study, there was a wide maintenance dosing range for all patients of 4.2-14.8 mg/kg/day. This includes five patients for whom higher dosing was required to maintain therapeutic levels, emphasizing that TDM and customized dosing of voriconazole is essential.
Our data suggest that utilizing adjusted body weight when dosing voriconazole in obese patients is a sensible strategy. This dosing scheme likely prevented more first steady-state supratherapeutic troughs in obese patients. The adjusted body weight maintenance dose in the obese group of 8.5 mg/kg/day is in line with package insert dosing for invasive fungal infections and offers a benefit for clinicians of only having to remember one dosing regimen for this drug, provided an adjusted body High-dose voriconazole monitoring and adjusted weight dosing JAC weight is utilized in obese patients. This may indicate a more broad appeal to application of this dosing strategy outside of the population that we have studied. 9 Koselke et al. 15 assessed differences in voriconazole trough serum levels using total body weight, adjusted body weight and ideal body weight for obese patients (BMI 35 kg/m 2 ) who received voriconazole 8 mg/kg/day. For 21 patients who were treated using total body weight dosing, 14 (67%) had supratherapeutic trough levels (.5.5 mg/L), and only 6 (29%) had therapeutic trough levels (2-5.5 mg/L). Using adjusted body weight dosing, 8 of 10 (80%) patients had voriconazole trough levels in the therapeutic range and none had a level .5 mg/L. Of 11 patients who were treated by using ideal body weight, 3 (27%) had supratherapeutic trough levels, 5 (45%) therapeutic trough levels and 3 (27%) subtherapeutic trough levels. These results are consistent with ours in that adjusted body weight appears to give appropriate voriconazole trough levels in obese patients.
Our maintenance dose definition occurred at least 15 days into therapy, which we think is appropriate for patients receiving prolonged treatment with voriconazole for invasive fungal infections. 9, 16 However, maintenance dosing was assessed in only 73% of patients. This was most often because of adverse effects of voriconazole, including CNS toxicity and periostitis. Some patients also experienced consistently variable troughs, so that they never met the maintenance definition, including one patient who had 34 voriconazole levels drawn over a 10 month period without having three consecutive troughs measured in the therapeutic range. Other patients did not achieve a maintenance dose due to persistently subtherapeutic levels despite increasing voriconazole doses, such that therapy was usually changed to itraconazole. Seven patients who had a first steady-state trough for analysis died before a maintenance trough could be accomplished.
Voriconazole metabolism can vary considerably between patients and within individual patients over time. Our patients experienced a wide maintenance dose range of 5.0-13.9 mg/kg/day in the obese and 4.2-14.8 mg/kg/day in the non-obese groups. In the obese group the maintenance dose was 15% lower than at the time of the first therapeutic trough at 8.6 versus 10 mg/kg/day. The consistent need for dose lowering in most of our population may have been due to the non-linear, or saturable, pharmacokinetics of voriconazole. In contrast the patients who required persistently escalating doses may have been experiencing autoinduction of cytochrome P450 enzymes. 17, 18 Both types of metabolism should be considered when performing TDM in patients treated with voriconazole.
There are some limitations to our study. First, it was a retrospective, single-centre experience. Second, it is unknown whether using an ideal body weight strategy in obese patients would have produced similar results to the adjusted weight method. However, we did not assess ideal body weight dosing because we felt the risk for having subtherapeutic levels was high and particularly undesirable when treating CNS infections. Third, assumptions about compliance and timing were made for the measurements of voriconazole trough levels in outpatients. However, we felt these assumptions were usually valid because all outpatients were followed closely by a fungal outbreak clinic pharmacist. This pharmacist, along with inpatient pharmacists who monitored patients while they were hospitalized, also assessed for voriconazole drug-drug interactions. Lastly, this study was not designed to correlate voriconazole levels with clinical outcomes.
In conclusion, a high-dose 12 mg/kg/day regimen of voriconazole had to be dose adjusted downward by nearly 30% in order to maintain most patients in the therapeutic 2-5 mg/L trough range. Use of an adjusted body weight dosing method in obese patients resulted in half of first steady-state troughs in the therapeutic range, and a nearly identical maintenance dose to that of total body weight dosing in the non-obese group. This appears to be a sensible dosing strategy for obese patients who have invasive fungal infections.
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